Okogen, Inc., a clinical-stage biotechnology company developing a host-directed antiviral platform, today announced that the first patient has been dosed in the EMERALD Trial, its multicenter Phase 1/2 clinical study evaluating Treyegen™ (OKG-0303) for acute infectious conjunc...

Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, ...

Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (NASDAQ: ORGS), strengthening the company’s lead ophthalmic program a...